HeartBeam Provides Update on Regulatory Path Following FDA Decision on 12-Lead ECG Synthesis Software Application ...
HeartBeam (BEAT) announced its regulatory strategy following receipt of a Not Substantially Equivalent, or NSE, decision on the company’s 510(k) ...
Recognized As A Top Global Innovator In Portable ECG Technology. <li /> The company was ranked second worldwide out of 243 companies evaluated in 12-lead ECG innovation in PatentVest's“Total Cardiac ...
In conclusion, HeartBeam’s earnings call reveals a company at a pivotal juncture, balancing significant progress with financial constraints. The overall sentiment is cautiously optimistic, with key ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced it ...
Reports Q3 2025 Results As FDA Review Nears Completion And Commercial Readiness Accelerates. HeartBeam (NASDAQ: BEAT) reported third-quarter 2025 results and highlighted continued progress toward ...
A 52-year-old man hospitalized with chest pain is found to have a slow heart rate and evidence of heart block. What does an ...
Life science educators across universities and healthcare training institutions are placing increasing emphasis on accurate clinical skills training, particularly for procedures that rely on precise ...
After spending years battling with Apple Inc. over the consumer heart monitoring market Alivecor Inc. is hoping to bring its technology to the professional health care market with its new device, ...
A 94-year-old female with history of hypertension, chronic kidney disease, and hyperlipidemia presents to the emergency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback